New appointment at MorphoSys
This article was originally published in Scrip
MorphoSys (Germany) has appointed Dr Arndt Schottelius as its first chief development officer, effective December 29th. He will be responsible for co-ordinating the company's expanding therapeutic antibody development activities, including preclinical and clinical drug development. Dr Schottelius joins from Genentech, where he most recently served as medical director of immunology development.